Merck & Co Inc

NYSE:MRK   3:59:57 PM EDT
77.24
-0.30 (-0.39%)
4:00:00 PM EDT: $77.22 -0.02 (-0.03%)
Regulatory, Earnings Announcements

Hetero Announces Interim Results From Phase III Trials Of Molnupiravir Conducted In India

Published: 07/09/2021 06:21 GMT
Merck & Co Inc (MRK) - Announces Interim Clinical Results From Phase Iii Clinical Trials of Molnupiravir Conducted in India.
Trial Shows Earlier Sars Cov-2 Rt-pcr Negativity Observed in Molnupiravir Group Versus Standard of Care.
Trial Shows Fewer Hospital Admissions in Molnupiravir Group Versus Standard of Care Alone.
Approached Drug Regulator to Seek Emergency Use Authorization for Molnupiravir in India.
Further Company Coverage: Mrkn ((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $12.54 Billion
Adjusted EPS is expected to be $1.44

Next Quarter Revenue Guidance is expected to be $12.17 Billion
Next Quarter EPS Guidance is expected to be $1.62

More details on our Analysts Page.